Sana Biotechnology, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held by Sana Biotechnology, Inc. on June 4, 2026. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Seattle, Washington.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Stockholders elected all three Class II director nominees (Hans E. Bishop, Robert Nelsen, and Alise S. Reicin, M.D.) to serve three-year terms expiring in 2029.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding and the percentage of votes cast for each director nominee to assess shareholder support levels.
- Confirm the specific terms of the engagement with Ernst & Young LLP for the 2026 fiscal year.
- Review the definitive proxy statement filed on April 24, 2026, for detailed biographies of the elected directors and the rationale for the auditor selection.